Strong stomach required by Elan shareholders
This article was originally published in Scrip
Elan's shareholders are going to need a strong stomach if they are to swallow the Irish firm's latest proposal to generate value with its fresh pot of cash. Based on the most optimistic forecasts for sales of the basket of respiratory products in which it has just acquired a royalty interest, stockholders can look forward to an average annual return over the next four years of just 0.7% of the current share price of $11.61 in the form of a cash dividend linked to those royalties.
You may also be interested in...
Fundraising in the life sciences sector has been booming even as firms in many other industries are struggling to stay in business. Goodwin’s David Mardle is upbeat about the sector’s ongoing prospects – although M&A deals are currently proving tricky to complete.
See how much the CEOs and R&D heads of the world’s biggest pharma companies get paid, and how those companies are performing.
Merck & Co is gradually catching up with Roche in PD-1/L1 first-line triple-negative breast cancer treatment, but its presentation at ASCO on Keynote-355 includes mixed PFS results. Overall survival data will be key to Keytruda’s competitiveness.